Monoclonal antibodies have transformed cancer treatment, with approved therapeutics predominantly belonging to the immunoglobulin G (IgG) class. These IgG therapeutics achieve antitumor activity largely via their Fc domains, which interact with immune cell receptors and activate downstream effector programs. The review outlines the rationale for modifying Fc structure and composition to improve antitumor efficacy and to reduce immunological side effects.
Antitumor mechanisms mediated by the antibody Fc include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). These functions are initiated when the Fc region of IgG engages Fcγ receptors on immune effector cells, thereby recruiting and activating cellular or complement pathways that target tumor cells. Effective therapeutic design depends on optimizing these Fc–FcγR interactions to achieve the desired immune response.
Despite clinical success, limitations persist. Approved IgG therapeutics can display suboptimal effector engagement—meaning that Fc interactions may not fully recruit or activate immune effectors in all contexts. In addition, adverse immunological effects can arise from unwanted or excessive immune activation. These constraints motivate engineering efforts to tune Fc properties for improved therapeutic index.
One major approach to improve antibody function is through targeted Fc mutations. Mutations can be designed to either enhance effector engagement or to silence Fc functions when effector activity is undesirable. Structural models of monoclonal IgG illustrate residues that have been mutated for different goals: residues mutated to silence effector functions, residues that alter glycosylation status (e.g., loss of glycan), residues engineered to enhance stability, and residues introduced to increase Fc-effector activity. The review highlights that mutation design is used to modulate receptor binding, stability, and immune recruitment.
The Fc region of IgG commonly carries a complex biantennary N-linked glycan attached at asparagine 297 (N297) on the heavy chain. The composition of this glycan (for example, presence or absence of fucose, galactose, sialic acid) influences Fcγ receptor binding and downstream effector functions. Glycan modification is therefore a deliberate engineering strategy to alter ADCC, ADCP, and CDC activity. Removal of glycosylation—such as via the N297A mutation—has been used to silence Fc effector functions, illustrating the functional importance of the N297 glycan.
Choice of Ig isotype is another lever for tuning antibody behavior. Distinct IgG isotypes have different intrinsic affinities for Fcγ receptors and varying propensities for activating complement. The review calls attention to isotype-specific phenomena such as IgG4 arm-exchange, a unique property of IgG4 in which half-molecule exchange can yield antibodies with mixed specificities and altered functional profiles. Isotype selection or modification can therefore be applied to achieve desired activation or to limit effector responses.
Structural illustrations in the review map mutation sites and glycan locations on a monoclonal IgG model. The figures categorize mutated residues by intended effect: silencing effector functions, removing glycosylation (notably N297A), enhancing structural stability, and increasing Fc-effector engagement. A separate figure depicts the complex biantennary glycan structure typically found at N297, with component monosaccharides labeled. These structural targets guide rational protein-engineering strategies.
Fc-engineering aims to address the dual goals of enhancing therapeutic efficacy and reducing adverse immunological events. Strategies discussed include combining different engineering approaches—mutations, glycan remodeling, and isotype choice—to fine-tune how antibodies engage Fcγ receptors and complement. The review presents Fc-engineering as a pathway toward next-generation monoclonal antibodies that better tailor immune interactions for oncology indications.
The authors report that there are no competing interests associated with this manuscript.